These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1168 related articles for article (PubMed ID: 33743799)
1. Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults. Self WH; Stewart TG; Wheeler AP; El Atrouni W; Bistran-Hall AJ; Casey JD; Cataldo VD; Chappell JD; Cohn CS; Collins JB; Denison MR; de Wit M; Dixon SL; Duggal A; Edwards TL; Fontaine MJ; Ginde AA; Harkins MS; Harrington T; Harris ES; Hoda D; Ipe TS; Jaiswal SJ; Johnson NJ; Jones AE; Laguio-Vila M; Lindsell CJ; Mallada J; Mammen MJ; Metcalf RA; Middleton EA; Mucha S; O'Neal HR; Pannu SR; Pulley JM; Qiao X; Raval JS; Rhoads JP; Schrager H; Shanholtz C; Shapiro NI; Schrantz SJ; Thomsen I; Vermillion KK; Bernard GR; Rice TW; Trials; 2021 Mar; 22(1):221. PubMed ID: 33743799 [TBL] [Abstract][Full Text] [Related]
2. Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults. Self WH; Stewart TG; Wheeler AP; El Atrouni W; Bistran-Hall AJ; Casey JD; Cataldo VD; Chappell JD; Cohn CS; Collins JB; Denison MR; de Wit M; Dixon SL; Duggal A; Edwards TL; Fontaine MJ; Ginde AA; Harkins MS; Harrington T; Harris ES; Hoda D; Ipe TS; Jaiswal SJ; Johnson NJ; Jones AE; Laguio-Vila M; Lindsell CJ; Mallada J; Mammen MJ; Metcalf RA; Middleton EA; Mucha S; O'Neal HR; Pannu SR; Pulley JM; Qiao X; Raval JS; Rhoads JP; Schrager H; Shanholtz C; Shapiro NI; Schrantz SJ; Thomsen I; Vermillion KK; Bernard GR; Rice TW Res Sq; 2021 Mar; ():. PubMed ID: 33688640 [No Abstract] [Full Text] [Related]
3. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308 [TBL] [Abstract][Full Text] [Related]
4. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial. Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T; Trials; 2021 May; 22(1):343. PubMed ID: 34001215 [TBL] [Abstract][Full Text] [Related]
5. Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19: A Blinded, Randomized, Placebo-Controlled Trial. Self WH; Wheeler AP; Stewart TG; Schrager H; Mallada J; Thomas CB; Cataldo VD; O'Neal HR; Shapiro NI; Higgins C; Ginde AA; Chauhan L; Johnson NJ; Henning DJ; Jaiswal SJ; Mammen MJ; Harris ES; Pannu SR; Laguio-Vila M; El Atrouni W; de Wit M; Hoda D; Cohn CS; McWilliams C; Shanholtz C; Jones AE; Raval JS; Mucha S; Ipe TS; Qiao X; Schrantz SJ; Shenoy A; Fremont RD; Brady EJ; Carnahan RH; Chappell JD; Crowe JE; Denison MR; Gilchuk P; Stevens LJ; Sutton RE; Thomsen I; Yoder SM; Bistran-Hall AJ; Casey JD; Lindsell CJ; Wang L; Pulley JM; Rhoads JP; Bernard GR; Rice TW; Chest; 2022 Nov; 162(5):982-994. PubMed ID: 35780813 [TBL] [Abstract][Full Text] [Related]
6. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial. Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ Trials; 2021 May; 22(1):342. PubMed ID: 34001174 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Diago-Sempere E; Bueno JL; Sancho-López A; Rubio EM; Torres F; de Molina RM; Fernández-Cruz A; de Diego IS; Velasco-Iglesias A; Payares-Herrera C; Flecha IC; Avendaño-Solà C; Palomino RD; Ramos-Martínez A; Ruiz-Antorán B Trials; 2021 Jan; 22(1):70. PubMed ID: 33472681 [TBL] [Abstract][Full Text] [Related]
8. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Devos T; Geukens T; Schauwvlieghe A; Ariën KK; Barbezange C; Cleeren M; Compernolle V; Dauby N; Desmecht D; Grimaldi D; Lambrecht BN; Luyten A; Maes P; Moutschen M; Romano M; Seyler L; Nevessignsky MT; Vandenberghe K; van Griensven J; Verbeke G; Vlieghe E; Yombi JC; Liesenborghs L; Verhamme P; Meyfroidt G Trials; 2020 Nov; 21(1):981. PubMed ID: 33246499 [TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
10. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Bégin P; Callum J; Heddle NM; Cook R; Zeller MP; Tinmouth A; Fergusson DA; Cushing MM; Glesby MJ; Chassé M; Devine DV; Robitalle N; Bazin R; Shehata N; Finzi A; McGeer A; Scales DC; Schwartz L; Turgeon AF; Zarychanski R; Daneman N; Carl R; Amorim L; Gabe C; Ellis M; Sachais BS; Loftsgard KC; Jamula E; Carruthers J; Duncan J; Lucier K; Li N; Liu Y; Armali C; Kron A; Modi D; Auclair MC; Cerro S; Avram M; Arnold DM Trials; 2021 May; 22(1):323. PubMed ID: 33947446 [TBL] [Abstract][Full Text] [Related]
11. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial. Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671 [TBL] [Abstract][Full Text] [Related]
12. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. O'Donnell MR; Grinsztejn B; Cummings MJ; Justman JE; Lamb MR; Eckhardt CM; Philip NM; Cheung YK; Gupta V; João E; Pilotto JH; Diniz MP; Cardoso SW; Abrams D; Rajagopalan KN; Borden SE; Wolf A; Sidi LC; Vizzoni A; Veloso VG; Bitan ZC; Scotto DE; Meyer BJ; Jacobson SD; Kantor A; Mishra N; Chauhan LV; Stone EF; Dei Zotti F; La Carpia F; Hudson KE; Ferrara SA; Schwartz J; Stotler BA; Lin WW; Wontakal SN; Shaz B; Briese T; Hod EA; Spitalnik SL; Eisenberger A; Lipkin WI J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 33974559 [TBL] [Abstract][Full Text] [Related]
13. A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol. Misset B; Hoste E; Donneau AF; Grimaldi D; Meyfroidt G; Moutschen M; Compernolle V; Gothot A; Desmecht D; Garigliany M; Najdovski T; Laterre PF BMC Pulm Med; 2020 Dec; 20(1):317. PubMed ID: 33287790 [TBL] [Abstract][Full Text] [Related]
16. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927 [TBL] [Abstract][Full Text] [Related]
17. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial. Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial. Gaborit B; Vanhove B; Vibet MA; Le Thuaut A; Lacombe K; Dubee V; Ader F; Ferre V; Vicaut E; Orain J; Le Bras M; Omnes A; Berly L; Jobert A; Morineau-Le Houssine P; Botturi K; Josien R; Flet L; Degauque N; Brouard S; Duvaux O; Poinas A; Raffi F; Trials; 2021 Mar; 22(1):199. PubMed ID: 33750432 [TBL] [Abstract][Full Text] [Related]